



Sigma-1 Receptor in Health and Disease

Guest Editor:

Dr. Shao-Ming Wang

1. Graduate Institute of
Biomedical Sciences, China
Medical University, Taichung
404333, Taiwan
2. Neuroscience and Brain
Disease Center, China Medical
University, Taichung 404333,
Taiwan

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Our Special Issue focuses on the biological function of the Sigma-1 receptor in health and diseases. Specifically, it explores research trends in Sigma-1R-related areas, to assess their potential for the treatment of diseases. The scope of the Special Issue includes neurobiology, cancer biology, inflammation-related diseases, biomedicines, signal transduction, nuclear and cytosol transport, gene regulation, cell death, and cell biology. Currently, more studies are focusing on the new biological functions of Sigma-1R in neurological diseases. We encourage not only neuroscientists but also researchers from other fields to submit manuscripts for this Special Issue. Hopefully, the Sigma-1R can be used as a translational therapeutic target for the treatment of various diseases.

Dr. Shao-Ming Wang
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)